Skip to main content
European Commission logo
Deutsch Deutsch
CORDIS - Forschungsergebnisse der EU
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Development of a connexon-proteoliposome delivery system to ameliorate inflammatory and mechanical stress responses in the regeneration of osteoarthritic cartilage

Projektbeschreibung

Intelligente Knorpelgerüste gegen Arthrose

Erkrankungen wie Arthrose, die mit Knorpeldegeneration einhergehen, werden mit gezüchteten Gerüsten behandelt. Um deren regeneratives Potenzial jedoch maximal ausschöpfen zu können, muss zielgenauer vorgegangen werden. Das EU-finanzierte Projekt ChondroCONNECT wird versuchen, Connexine der sog. Gap Junctions zu nutzen, um kleine Moleküle mit mutmaßlich regenerativem Potenzial zu übertragen. Im Mittelpunkt der Arbeiten steht dabei Cx43, das in Knorpel am häufigsten vorkommt und als therapeutischer Angriffspunkt für Arthrose gilt. Das Forschungsteam wird die genaue Rolle des Cx43 bei der Arthrose untersuchen und eine Plattform entwickeln, mit der sich Cx43 ausschalten und ein gesunder Stoffwechsel wiederherstellen lässt. Mit künstlich erzeugten Connexin-haltigen Proteoliposomen wird ChondroCONNECT die bestehenden Strategien für den Wiederaufbau des Knorpels bei Arthrose verbessern können.

Ziel

Regenerative medicine strategies using engineered scaffolds have shown promise to regenerate cartilage in degenerative conditions (e.g. osteoarthritis, OA). However, it is clear further cues are required to control repair in situ. Small interfering (si)RNA can control protein expression but current cell delivery methods require endosome escape, limiting efficacy. Cell delivery of small molecules through connexons (Cx) bypasses the endosome and can be achieved by gap junction formation between cells and engineered Cx-containing proteoliposomes (Cx-PL). The most abundant connexin (Cx43) in cartilage cells (chondrocytes) is also a promising OA therapeutic target. It is highly upregulated in OA and is linked to inflammation, senescence, metabolic shifts and gene regulation. However, many questions remain on its mechanistic role in the disease. This project focuses on Cx43 as a therapeutic target and a delivery mechanism and aims to i) Investigate Cx43 roles in response to OA-associated proinflammatory and mechanical stimuli ii) Develop a Cx-PL delivery platform to knockdown Cx43 and restore healthy metabolism in OA. To study this I will assess chondrocyte responses to proinflammatory and mechanical signalling while controlling Cx43 expression and activity in culture. Using untargeted metabolomics, I will identify key responsive metabolic pathways and perform in vitro screens of the effects of supplementing these to promote healthy phenotypes. Finally, I will encapsulate Cx43-siRNA and a selected bioactive metabolite in Cx43-PLs, incorporate these into a collagen I-hyaluronic acid scaffold and test this delivery platform in vitro. This fellowship conducted with Prof. O’Brien at the Royal College of Surgeons in Ireland will enable me to build on my existing skills in two emerging fields- siRNA therapy and PL-delivery, while the exceptional training environment at RCSI will allow me to refine complementary skills that will expedite my research independence.

Koordinator

ROYAL COLLEGE OF SURGEONS IN IRELAND
Netto-EU-Beitrag
€ 196 590,72
Adresse
ST STEPHEN'S GREEN 123
2 Dublin
Irland

Auf der Karte ansehen

Region
Ireland Eastern and Midland Dublin
Aktivitätstyp
Higher or Secondary Education Establishments
Links
Gesamtkosten
€ 196 590,72